Skip to content

Article: Nicotinamide Riboside Reduces Liver Inflammation in Alcoholic Liver Disease: Preclinical Findings

Nicotinamide Riboside Reduces Liver Inflammation in Alcoholic Liver Disease: Preclinical Findings


Synopsis

Alcoholic liver disease (ALD) is a serious liver condition caused by excessive alcohol and has few effective nutritional treatments. Researchers found that brown fat cells release a protein called eNAMPT, which contributes to liver inflammation by activating the NLRP3 inflammasome in liver cells and immune cells. In experiments, removing eNAMPT reduced liver inflammation. Importantly, giving nicotinamide riboside (NR), a form of vitamin B3, suppressed eNAMPT release and lowered liver inflammation in both cells and mice. This suggests that NR could be a promising dietary strategy to reduce liver inflammation in ALD by targeting eNAMPT.

Journal

Food & Function

Read more

Cardiovascular Disease

Nicotinamide Riboside Supplementation Combined with Exercise May Improve Nighttime Blood Pressure and Arterial Stiffness: Clinical Findings

Objectives To evaluate whether combining aerobic exercise with nicotinamide riboside (NR) could enhance blood pressure (BP) control in sedentary older adults with hypertension. Journal GeroScience...

Read more
Case Studies

Nicotinamide Riboside-Containing β-Hydroxybutyrate Supplementation (NHS101) in Children with Multiple Acyl-CoA Dehydrogenase or Pyruvate Dehydrogenase Deficiency: Case Report

Objective To evaluate the efficacy of a new preparation of dextro-β hydroxybutyrate salt mixture containing NR (NHS101) in patients with metabolic disorders affecting energy metabolism, specificall...

Read more